Question: Is Long-Term Proton Pump Inhibitor Use Necessary for Managing Chronic Gastroesophageal Reflux Disease? A Critical Analysis of Clinical Practice Guidelines and Pharmacological Treatment

Expert answer

DRAFT / STUDY TIPS: Is Long-Term Proton Pump Inhibitor Use Necessary for Managing Chronic Gastroesophageal Reflux Disease? A Critical Analysis of Clinical Practice Guidelines and Pharmacological Treatment

Introduction

Gastroesophageal reflux disease (GERD) is a prevalent condition characterized by persistent acid reflux, leading to symptoms such as heartburn and nausea. Patients frequently require pharmacological intervention to manage symptoms effectively. The case of Lalisa Makok, a 55-year-old female experiencing daily heartburn and nausea following the discontinuation of omeprazole, raises important questions regarding long-term proton pump inhibitor (PPI) use, clinical practice guidelines (CPGs) for GERD management, and the appropriate pharmacological interventions to ensure symptom relief while minimizing potential risks. This paper critically examines the CPG recommendations, evaluates the pharmacological treatment options, and reflects on the necessary follow-up assessments for optimal patient care.

Patient Case Analysis

Lalisa Makok presents to the clinic with recurrent daily heartburn and nausea, which began after stopping an eight-week omeprazole trial. Her medical history includes high cholesterol, managed with rosuvastatin. She has no history of smoking, drinks alcohol minimally, and has a BMI of 28.2, placing her in the overweight category. Her vital signs are stable, with a blood pressure of 114/68 mmHg and a heart rate of 63 bpm. Given her symptoms' recurrence after discontinuation of omeprazole, the NP has decided to send her for a diagnostic endoscopy, following the CPG recommendations.

Clinical Practice Guideline Recommendations

The current American College of Gastroenterology (ACG) guidelines for GERD management emphasize the stepwise approach to treatment, starting with lifestyle modifications and pharmacotherapy as needed. PPIs, such as omeprazole, are the most effective treatment for GERD, particularly in patients with persistent symptoms. The guidelines recommend an initial eight-week course of PPIs, after which patients should be assessed for symptom recurrence. If symptoms return upon discontinuation, long-term PPI therapy or alternative treatments, such as H2-receptor antagonists (H2RAs), may be considered (Katz et al., 2022).

Additionally, the American Gastroenterological Association (AGA) 2022 guidelines recommend endoscopic evaluation for patients with recurrent GERD symptoms after stopping PPIs, particularly if symptoms are frequent and impact quality of life. This aligns with the NP’s decision to refer Lalisa for a diagnostic endoscopy. The CPG also suggests a step-down approach, where PPIs are tapered instead of abruptly discontinued, or a switch to H2RAs may be explored to reduce rebound acid hypersecretion (Spechler et al., 2021).

Pharmacological Treatment Considerations

Given Lalisa’s symptom recurrence after discontinuing omeprazole, a pharmacological approach is necessary to manage her condition effectively.

1. Proton Pump Inhibitors (PPIs) as the Primary Treatment

PPIs are the most effective therapy for GERD, reducing gastric acid secretion by inhibiting the H+/K+ ATPase enzyme in the stomach lining. Omeprazole effectively controlled Lalisa’s symptoms during the initial trial, indicating that PPI therapy was beneficial for her. Given her symptom recurrence, a long-term, lowest-effective-dose approach could be considered to balance efficacy and minimize potential risks, such as osteoporosis, vitamin B12 deficiency, and kidney disease associated with prolonged PPI use (Vaezi et al., 2018).

2. H2-Receptor Antagonists (H2RAs) as an Alternative

If long-term PPI use is not preferred, H2RAs such as famotidine could be an alternative. H2RAs are less potent than PPIs but still provide symptomatic relief by blocking histamine receptors in the stomach. However, they may be less effective for severe GERD and are associated with tolerance over time (Scarpignato et al., 2016). Given Lalisa’s persistent symptoms, H2RAs may be considered if she prefers to avoid long-term PPI therapy.

3. Prokinetic Agents and Other Adjunct Therapies

Prokinetic agents, such as metoclopramide, may be useful in GERD patients with delayed gastric emptying, but their side effects (e.g., tardive dyskinesia) often limit their use. Other adjunctive measures, such as alginates (e.g., Gaviscon), may provide symptomatic relief by forming a protective barrier against acid reflux.

Professional Assessment and Recommendations

Lalisa’s case suggests PPI therapy was effective, but abrupt discontinuation led to symptom relapse, likely due to rebound acid hypersecretion. Given the ACG and AGA recommendations, the following pharmacological management plan is proposed:

1. Restart a PPI (e.g., omeprazole 20 mg once daily) for long-term symptom control. The lowest effective dose should be used to minimize adverse effects.
2. Gradual tapering of PPI therapy should be considered if discontinuation is attempted again in the future. A step-down approach, transitioning to H2RAs or alternate-day PPI dosing, may prevent rebound acid hypersecretion.
3. Consider adjunct therapy with alginates (e.g., Gaviscon) or H2RAs (famotidine) as needed. This may help in cases of breakthrough symptoms.
4. Lifestyle modifications should be reinforced, including:
   • Avoiding late-night meals and lying down immediately after eating.
   • Limiting dietary triggers such as spicy foods, caffeine, and alcohol.
   • Weight management strategies, given her BMI of 28.2.

Additional Considerations and Follow-Up

Several follow-up assessments and questions should be addressed to optimize Lalisa’s treatment plan:

1. Endoscopy Results: The NP's referral for diagnostic endoscopy is crucial to rule out complications such as Barrett’s esophagus, esophagitis, or peptic strictures.
2. H. pylori Testing: Given her recurrent symptoms, testing for Helicobacter pylori should be considered, as eradication can improve GERD management (Chey et al., 2017).
3. Bone Health and PPI Risks: If long-term PPI therapy is needed, periodic assessments for osteoporosis risk (e.g., bone mineral density scans) should be considered.
4. Lipid Management: Given her high cholesterol, monitoring the interaction between rosuvastatin and PPIs should be reviewed, though evidence suggests minimal interaction.
5. Patient Preferences: Engaging Lalisa in shared decision-making regarding long-term medication use, potential risks, and alternative therapies will ensure adherence and optimal health outcomes.

Conclusion

Lalisa Makok's case underscores the complexity of GERD management, particularly in patients experiencing symptom recurrence post-PPI discontinuation. Based on current ACG and AGA guidelines, the best course of action involves restarting PPI therapy at the lowest effective dose while considering long-term management strategies, including gradual tapering and adjunct treatments such as H2RAs or alginates. The diagnostic endoscopy is essential to rule out complications, and additional assessments should be conducted to optimize patient outcomes. Ensuring comprehensive follow-up and incorporating patient preferences into treatment decisions will lead to effective symptom control while minimizing risks associated with long-term PPI use.